Clinical Studies

Necrotizing Meningoencephalitis in Pugs (PDE) is a devastating disease. Clinical signs include seizures, circling, cognitive changes, and visual deficits. Our goal is to identify neurological abnormalities in Pugs with high genomic risk for PDE before the onset of the above-mentioned advanced clinical signs.

This clinical trial will evaluate the effectiveness of a novel investigational product for the treatment of oral melanoma in dogs.

Xylitol is an artificial sweetener commonly found in sugar-free gum. Although safe for humans, xylitol is highly toxic to dogs. This study will compare the liver protective capacity of two veterinary liver protectant products in dogs suffering from xylitol toxicity.

Postoperative regurgitation is a common side effect of general anesthesia; it is of clinical concern due to the increased risk of pneumonia. This study seeks to define the rate at which intravenously administered MNTX in healthy dogs is metabolized. Once defined, a future study will evaluate the efficacy of this treatment in reducing postoperative regurgitation in dogs.

Intestinal dysbiosis has been associated with tumor progression of colorectal, lung, and breast cancer in human patients. The objective of this study is to determine whether or not canine patients diagnosed with osteosarcoma have intestinal dysbiosis and if the presence of intestinal dysbiosis is associated with metastasis in these patients.

Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

Immune-mediated thrombocytopenia (ITP) is a disorder characterized by severely low platelets due to attack by white blood cells. This is often associated with bruising and occasionally severe bleeding episodes.

This pilot study in dogs with suspected cranial cruciate ligament rupture seeks to determine whether a benefit is seen through the intra-articular injection of a novel veterinary device product in the affected stifle joint.

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

This is an exploratory study to evaluate the safety and effectiveness of concomitant intraarticular (IA) and peri-neural (PN) injections of an investigational veterinary product for the control of elbow pain in dogs. This 28-day study also includes a long term follow up at 3 and 6 months.

The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog.